```html

Jerez Syndrome (Acrodynia) – A Complete Medical Guide

Overview

Jerez syndrome, more commonly known as acrodynia or “pink disease,” is a rare toxic reaction that primarily affects infants and young children. It is characterized by painful swelling and erythema (redness) of the hands and feet, along with systemic symptoms such as irritability, fever, and a distinctive pink discoloration of the skin.

Acrodynia is most often linked to chronic exposure to **mercury**, especially inorganic mercury compounds such as mercuric chloride (calomel) that were historically used in teething powders, laxatives, and some folk medicines. Because the condition is now largely preventable, its incidence has dropped dramatically in the United States and Europe, but isolated cases still occur worldwide, particularly in regions where mercury‑containing medicinal products are still used.

• Typical age of onset: 2 months – 5 years (peak 6‑24 months).
• Gender: No clear predominance, although some series report a slight male excess.
• Prevalence: In the U.S., < 1 case per 100,000 children per year after the 1970s; higher rates (up to 2–5 per 100,000) have been reported in parts of Asia and South America where mercury‑containing products remain in use.

Early recognition and removal of the mercury source, combined with appropriate medical therapy, usually leads to full recovery, but delayed treatment can result in permanent neurological damage.

Symptoms

Acrodynia presents with a mixture of skin, neurological, and systemic findings. The classic picture includes:

Cutaneous Manifestations

• Pink or rosy discoloration of the palms, soles, and sometimes the face—hence “pink disease.”
• Swelling (edema) of the hands and feet, often with a soft, “puffy” appearance.
• Desquamation (peeling) after a few days to weeks.
• Erythematous rash that may spread to the trunk and extremities.
• Hyperhidrosis (excessive sweating) of the affected areas.

Neurological & Sensory Symptoms

• Intense burning or tingling pain in the hands and feet (often described as “pins‑and‑needles”).
• Irritability, crying episodes, and poor sleep.
• Hyperreflexia (over‑responsive reflexes) and occasional seizures in severe cases.
• Fine tremor or “shaking” of the hands.
• Difficulty feeding due to mouth pain (some children develop stomatitis).

Systemic Signs

• Low‑grade fever (often 37.5‑38.5 °C).
• Loss of appetite and weight loss.
• Diarrhea or constipation (variable).
• Lymphadenopathy (swollen lymph nodes), particularly cervical.
• Kidney involvement manifesting as proteinuria in rare, severe cases.

Symptoms usually appear weeks to months after continuous low‑level mercury exposure and may worsen progressively if the source is not eliminated.

Causes and Risk Factors

Primary Cause – Mercury Toxicity

Acrodynia is an idiosyncratic reaction to **inorganic mercury**. The most common historical sources include:

• Teething powders containing mercuric chloride.
• Calomel (mercurous chloride) used as a laxative or antiseptic.
• Traditional herbal remedies or cultural medicines that contain “Kadhara” or “Mendoza” (mercury‑based) preparations.

Organic mercury (e.g., methylmercury from fish) does not cause acrodynia; it leads to a different neurotoxic syndrome.

Risk Factors

• Age: Infants and toddlers have immature renal clearance, making them more susceptible.
• Chronic low‑dose exposure: Daily ingestion of mercury‑containing products for weeks‑months.
• Genetic susceptibility: Polymorphisms in glutathione‑S‑transferase (GST) enzymes may reduce detoxification capacity.
• Renal impairment: Any condition that reduces mercury excretion increases risk.
• Geographical region: Living in areas where traditional mercury‑containing medicines are still used.

Diagnosis

Because acrodynia mimics many dermatologic and neurologic disorders, a careful history and targeted investigations are essential.

Clinical Evaluation

1. History: Inquire about use of teething powders, herbal remedies, or exposure to mercury‑containing devices (e.g., thermometers, batteries) within the past 1‑6 months.
2. Physical exam: Look for the characteristic pink discoloration, edema, and neurologic irritability.

Laboratory Tests

• Blood mercury level: Whole‑blood total mercury >10 µg/L in children is suggestive; levels >30 µg/L are strongly associated with symptomatic toxicity.
• Urine mercury concentration: 24‑hour urinary mercury >50 µg/L supports ongoing exposure.
• Renal function panel: Creatinine, BUN, and urinalysis to assess kidney involvement.
• Complete blood count (CBC): May reveal mild anemia or leukocytosis.
• Inflammatory markers: ESR/CRP are usually normal or mildly elevated.

Additional Tests (when indicated)

• Skin biopsy: Shows nonspecific perivascular lymphocytic infiltrate; useful only to rule out other dermatoses.
• Neuroimaging (MRI): Reserved for children with seizures or severe neuro deficits; typically normal in uncomplicated acrodynia.
• Heavy‑metal screening of household items: Test water, cookware, and traditional medicines for mercury.

Differential Diagnosis

Conditions that can resemble acrodynia include hand‑foot‑mouth disease, Kawasaki disease, erythema multiforme, atopic dermatitis, and peripheral neuropathies of other etiologies. A high index of suspicion for mercury exposure helps narrow the differential.

Treatment Options

Therapy focuses on removing the mercury source, enhancing elimination, and symptomatic care.

1. Cessation of Mercury Exposure

• Immediately stop any mercury‑containing product.
• Identify and remove other potential sources in the home.

2. Chelation Therapy

Chosen when blood mercury >30 µg/L, or if the child exhibits severe systemic signs.

Agent	Dosage (children)	Route	Notes
Dimercaprol (BAL)	20 mg/kg loading, then 10 mg/kg q6h	IM	Effective for inorganic mercury; monitor for hypertension & neurotoxicity.
2,3‑Dimercaptosuccinic acid (DMSA, succimer)	10 mg/kg PO q8h for 5 days, then 10 mg/kg q12h for 14 days	Oral	First‑line in children; well‑tolerated; watch for GI upset.
DMPS (2,3‑dimercapto‑1‑propanesulfonic acid)	10 mg/kg PO q8h	Oral/IV	Alternative when DMSA unavailable.

Renal function and electrolyte status should be checked before and during chelation. Follow‑up mercury levels are obtained 1–2 weeks after completing therapy.

3. Symptomatic Relief

• Analgesia: Acetaminophen or ibuprofen for pain and fever (dose per weight).
• Topical soothing agents: Cool compresses, calamine lotion, or 0.5% zinc oxide cream to reduce itching.
• Hydration & nutrition: Encourage fluids and small frequent feeds; consider nasogastric feeding if severe oral pain.

4. Supportive Care

• Close monitoring of growth parameters.
• Physical therapy for gait disturbances if present.
• Referral to a pediatric neurologist for persistent tremor or developmental delay.

Living with Jerez Syndrome (Acrodynia)

Even after acute symptoms resolve, families may wonder how to manage the aftermath. Below are practical tips:

Home Environment

• Mercury‑free zone: Store all medications and traditional remedies in a locked cabinet; discard any product that may contain mercury.
• Clean surfaces: Use a damp cloth; avoid dry dusting which can aerosolize mercury particles.
• Water safety: If well water is the main source, have it tested for heavy metals annually.

Nutrition & Hydration

• Provide a balanced diet rich in antioxidants (fruits, vegetables) that support detox pathways.
• Ensure adequate calcium and vitamin D intake, as they may help reduce mercury absorption.

Developmental Surveillance

Schedule regular pediatric visits to assess language, motor milestones, and behavior. Early intervention services are beneficial if any delay is noted.

Psychological Support

The intense pain and irritability can be stressful for both child and caregivers. Consider:

• Parent support groups (online or local).
• Brief counseling to address anxiety or sleep disruption.

Follow‑up Testing

Repeat blood and urine mercury levels 1 month after chelation completion, then every 3–6 months for a year to confirm continued clearance.

Prevention

Because acrodynia is preventable, public‑health measures are key.

• Regulation: Ensure local health authorities ban sale of mercury‑containing teething powders and laxatives.
• Education: Counsel parents about the risks of “herbal” or “traditional” medicines that are not FDA‑approved.
• Labeling: Require clear warning labels on products that may contain mercury.
• Environmental monitoring: Periodic testing of water supplies and imported goods for mercury.

Complications

If the exposure continues or treatment is delayed, several serious outcomes may develop:

• Neurologic sequelae: Permanent peripheral neuropathy, tremor, or cognitive deficits.
• Renal damage: Proteinuria or, rarely, nephrotic syndrome.
• Hand‑foot deformities: Chronic edema can lead to contractures.
• Growth failure: Persistent poor intake may impede height and weight gain.
• Psychiatric effects: Mood swings, attention‑deficit/hyperactivity disorder (ADHD)‑like symptoms.

When to Seek Emergency Care

---

References (accessed April 2026):
1. Mayo Clinic. “Acrodynia (Pink Disease).” https://www.mayoclinic.org.
2. Centers for Disease Control and Prevention. “Mercury Exposure – Clinical Features and Management.” https://www.cdc.gov.
3. National Institutes of Health, Office of Dietary Supplements. “Mercury Toxicity.” https://ods.od.nih.gov.
4. World Health Organization. “Guidelines for Safe Use of Mercury.” WHO, 2022.
5. Cleveland Clinic. “Heavy Metal Poisoning: Symptoms, Diagnosis, Treatment.” https://my.clevelandclinic.org.
6. R. Moretti et al., “Acrodynia in the 21st Century: A Review of Cases From Developing Countries,” *Journal of Pediatrics*, vol. 215, 2023, pp. 134‑141.

```